Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 4 rlay-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patient
The article profiles five biotech/healthcare stocks and cites recent catalysts and upcoming events. Glaukos (GKOS) highlights Epioxa launch and raised 2026 sales guidance ahead of Q2 2026 results July 29, 2026. TG Therapeutics (TGTX) cites BRIUMVI trial updates and Q2 results early August. Corcept (CORT) points to Lifyorli progress and raised guidance. Relay (RLAY) and Nutex Health (NUTX) note Phase 3 and upcoming quarterly results. It lists large post-publication price gains for each.
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $19.58 ($0.94M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning RLAY (Relay Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RLAY coverage spans insider activity, financial news and earnings.
In the last 30 days, RLAY insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($83K). The most active reporter was Rahmer Peter, See remarks, with 1 filing.
New primary disclosures include updated cash position, follow-on offering proceeds, and specific clinical development timelines plus initial Phase 1/2 vascular-anomalies response metrics.
The trade setup is more medium-term, centered on trial enrollment progress updates rather than an immediate earnings catalyst.
This is an insider open-market sale under a pre-arranged 10b5-1 plan, with limited direct signal on near-term fundamentals.
This is a routine insider sale under a pre-arranged 10b5-1 plan, with limited direct signal for near-term fundamentals.
This is a disclosed insider sale, not a new fundamental catalyst, but it can modestly affect near-term sentiment and positioning.
alphai scores every news story that mentions RLAY with an AI model for sentiment and relevance, and aggregates insider trades from Relay Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 4 rlay-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patient
6 min readThe article profiles five biotech/healthcare stocks and cites recent catalysts and upcoming events. Glaukos (GKOS) highlights Epioxa launch and raised 2026 sales guidance ahead of Q2 2026 results July 29, 2026. TG Therapeutics (TGTX) cites BRIUMVI trial updates and Q2 results early August. Corcept (CORT) points to Lifyorli progress and raised guidance. Relay (RLAY) and Nutex Health (NUTX) note Phase 3 and upcoming quarterly results. It lists large post-publication price gains for each.
7 min readPatel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $19.58 ($0.94M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
2 min readRahmer Peter (See remarks) sold 50,000 shares of Relay Therapeutics, Inc. (RLAY) at $19.09 ($0.95M total) on 2026-06-30 under a Rule 10b5-1 trading plan.
1 min readCatinazzo Thomas (Chief Financial Officer) sold 187,163 shares of Relay Therapeutics, Inc. (RLAY) at an average of $16.97 ($16.97–$17.01, $3.18M total) across 4 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
2 min readBergstrom Donald A (President, R&D) sold 93,456 shares of Relay Therapeutics, Inc. (RLAY) at $16.94 ($1.58M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
2 min readRelay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001812364 --12-31 false 0001812364 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
2 min readRelay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.
1 min readRelay Therapeutics has announced a public stock offering aiming to raise $175 million. The biotechnology company is looking to secure additional capital through this offering to support its operations and research efforts.
3 min readRelay Therapeutics Inc is expected to report an earnings loss of 38 cents per share, according to a preview from Refinitiv. The article provides this key financial expectation for the company.
3 min read
